Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

tenofovir

- PMLiVE

Clinical trial of Gilead’s coronavirus hopeful remdesivir begins in US

National Institutes of Health initiates trial of experimental drug

- PMLiVE

China’s BrightGene successfully copies Gilead’s coronavirus hopeful remdesivir

Raises concerns over patent exclusivity in the country

- PMLiVE

FDA starts priority review of Kite’s CAR-T for mantle cell lymphoma

KTE-X19 is also under regulatory review with the EMA

- PMLiVE

HIV vaccine based on Sanofi/GSK components fails trial

Data suggested vaccine was no more effective than placebo

- PMLiVE

GSK and Gilead join global efforts to tackle novel coronavirus

Confirmed cases rise to over 17,000 in China

- PMLiVE

Keeping up the fight against HIV and using the lessons to tackle other threats

Danny Buckland interviews Gilead’s Mike Elliott

- PMLiVE

FDA rejects ViiV’s long-acting monthly HIV injection

Blow to company as it hopes to capture market share from Gilead

- PMLiVE

Gilead’s NASH hopes crushed as candidates fail again

Monotherapy and combination regimens produced disappointing results

- PMLiVE

Gilead owes BMS millions after losing Yescarta patent infringement trial

Jury found Gilead's CAR-T infringed on exclusive patent

- PMLiVE

CymaBay Therapeutics plummets after abandoning NASH drug

Failure of mid-stage liver disease candidate caused shares to slip over 75%

Novartis day

Novartis makes case for NASH candidate tropifexor

Race to market intensifies as rivals strive to win first-in-class

- PMLiVE

NIH, Gates pledge $200m for HIV and sickle cell gene therapies

Aim to bring therapies to patients in lower-income countries

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links